| P2093 | author name string | Yu Zhang | |
| | Ying Cao | |
| | Xiao-Yuan Xu | |
| | Hong-Li Xi | |
| | Min-Ran Li | |
| | Ren-Wen Zhang | |
| | Xia-Xia Zhang | |
| P2860 | cites work | EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 |
| | Hepatitis B virus infection--natural history and clinical consequences | Q29617961 |
| | Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients | Q33845546 |
| | Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients | Q35681979 |
| | Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment | Q35746110 |
| | Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration | Q37285762 |
| | Hepatitis B surface antigen monitoring and management of chronic hepatitis B. | Q37892655 |
| | First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice | Q38008777 |
| | Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues | Q38224440 |
| | Recent developments in antivirals against hepatitis B virus | Q38687338 |
| | Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion | Q39808366 |
| | Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B. | Q40857335 |
| | Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment | Q42212574 |
| | Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study | Q42254708 |
| | Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment | Q42264380 |
| | Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B. | Q42270462 |
| | Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. | Q42288752 |
| | Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 |
| | Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients | Q42865759 |
| | Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age. | Q43144573 |
| | Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants | Q43236273 |
| | Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma | Q44432605 |
| | Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection | Q45363144 |
| | Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers | Q45375655 |
| | Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. | Q45398888 |
| | One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. | Q45407168 |
| | Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy | Q45755644 |
| | Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study | Q46501449 |
| | Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance. | Q50972488 |
| | Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. | Q51174313 |
| | Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. | Q53361861 |
| | Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency | Q58235730 |
| | [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B] | Q79807058 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | entecavir | Q418586 |
| | chronic hepatitis B | Q55779876 |
| P304 | page(s) | 929-935 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Chinese Medical Journal | Q5100534 |
| P1476 | title | Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy | |
| P478 | volume | 129 | |